Nirsevimab for Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Infants: A Systematic Review of Randomized Controlled Trials
DOI:
https://doi.org/10.35730/y3teyv85Keywords:
Nirsevimab, respiratory syncytial virus, infants, monoclonal antibodyAbstract
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) and hospitalization in infants. Nirsevimab is a long-acting monoclonal antibody given as a single dose. This systematic review summarizes its efficacy and safety in randomized controlled trials (RCTs).
Methods: RCTs of nirsevimab in infants, reporting medically attended RSV LRTI or hospitalization, were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains.
Findings: Three RCTs (a phase 2b trial, MELODY, and HARMONIE; 11,001 randomized infants) were included. Efficacy against medically attended RSV LRTI was 70.1% (95% CI 52.3–81.2) in the phase 2b trial, 74.5% (95% CI 49.6–87.1) in MELODY, and 83.2% (95% CI 67.8–92.0) against RSV LRTI hospitalization in HARMONIE. Serious adverse events were similar between groups in the placebo-controlled trials.
Conclusion: Nirsevimab reduced RSV LRTI in infants across three trials, with an acceptable short-term safety profile. Data from Indonesia and tropical settings were not found.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dwi Novilolita, Vistaria Furkano, Sakinah Shadrina (Author)

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.